您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > PD-1/PD-L1 inhibitor 1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PD-1/PD-L1 inhibitor 1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PD-1/PD-L1 inhibitor 1图片
CAS NO:1675201-83-8
规格:98%
分子量:475.58
包装与价格:
包装价格(元)
5mg电议
25mg电议

产品介绍
PD-1/PD-L1 interaction inhibitor
CAS:1675201-83-8
分子式:C29H33NO5
分子量:475.58
纯度:98%
存储:Store at -20°C

Background:

IC50: 0.006-0.10 μM


PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.


Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. In preclinical animal models, it has been found that blocking the PD-1/PD-Ll pathway by monoclonal antibodies can enhance the immune response and result in tumor shrinkage or control of virus infection. Recent clinical studies have shown that the therapies with a monoclonal antibody to PD-Ll can give benefits to patients with advanced cancer.


In vitro: PD-1/PD-L1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1). PD-1/PD-L1 inhibitor 1 was also found to act as an immunomodulator. In preclinical studies, PD-1/PD-L1 inhibitor 1 was able to block PD-1/PD-Ll interactions with an IC50 value between 6 and 100 nM, which was measured by a homogenous time-resolved fluorescence (HTRF) binding assay. Thus, PD-1/PD-L1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis C [1].


In vivo: So far, there is no animal in vivo data reported for PD-1/PD-L1 inhibitor 1.


Clinical trial: Up to now, PD-1/PD-L1 inhibitor 1 is still in the preclinical development stage.


Reference:
[1] https://www. google.com/patents/WO2015034820A1